Myriad to Present 18 Studies at the 2019 Annual Clinical Genetics Meeting
March 21 2019 - 6:05AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized
medicine, today announced that its Myriad Women’s Health business
unit will present data from 18 studies at the 2019 Annual Clinical
Genetics Meeting (ACMG) being held April 2-6, 2019 in
Seattle.
“We are excited to be presenting new data across multiple
genetic tests at ACMG and to highlight our progress in advancing
precision medicine for women,” said James Goldberg, M.D., board
certified maternal fetal medicine specialist, medical geneticist
and chief medical officer, Myriad Women’s Health. “With our
continued research and collaborations, we strive to provide genetic
information that helps patients and families with making their
important healthcare decisions.”
Please visit Myriad Women’s Health at booth #632 to learn more
about our leading portfolio of women’s health products.
Follow Myriad on Twitter via @myriadgenetics and @MyrWomensHealth
and keep up to date with meeting news and updates by using the
hashtag #ACMGMtg19.
Featured Research at 2019 ACMG |
Product |
Abstract |
Presenting
Author |
Presentation Details |
myRisk® Hereditary Cancer |
Characteristics and Clinical Correlations of Somatic Mosaic Large
Rearrangements Identified by Pan Cancer NGS Panel Test |
Shujuan Pan |
Podium (#166)April 3, 2019 12:15 p.m. – 1:15 p.m. |
Clinical Utility of Testing for PALB2, ATM, CHEK2, NBN, BRIP1,
RAD51C, and RAD51D: Management Changes and Patient Adherence to
Provider Recommendations |
Katie Johansen Taber |
Poster: 197 April 4, 10:00 a.m. – 11:30 a.m. |
|
|
Fragile X Carrier Screening Accompanied by Genetic Consultation has
Clinical Utility in Populations Beyond Those Recommended by
Guidelines |
Katie Johansen Taber |
Poster: 903Apr 4, 10:00 a.m.-11:30 a.m. |
|
A Data-Driven Approach for Determining Optimal Content for Expanded
Carrier Screening Panels |
Rotem Ben-Shachar |
Poster: 924Apr 4, 10:30 a.m.-12:00 p.m. |
|
Sequencing as a First-line Methodology for Cystic Fibrosis Carrier
Screening |
Dale Muzzey |
Poster: 880Apr 5, 10:30 a.m.-12:00 p.m. |
|
Distinct Scaling Between Positive Predictive Value and Panel Size
for Expanded Carrier Screening, Noninvasive Prenatal Screening, and
Hereditary Cancer Screening |
Eerik Kaseniit |
Poster: 892Apr 5, 10:30 a.m.-12:00 p.m. |
|
Genetic-Ancestry Analysis on >95,000 Individuals Undergoing
Expanded Carrier Screening Reveals Limitations of Ethnicity-Based
Medical Guidelines |
Eerik Kaseniit |
Poster: 879Apr 4, 10:00 a.m.-11:30 a.m. |
Foresight®
Carrier Screen |
Rare Recessive Diseases Enriched in the Ashkenazi Jewish Population
but Omitted from Ethnicity-Specific Carrier Screening
Guidelines |
Eerik Kaseniit |
Poster: 902Apr 5, 10:30 a.m.-12:00 p.m. |
|
Assessing Internal Consistency of Carrier Screening Guidelines
Using Carrier Rates of 176 Conditions Across Seven Populations and
265,000 Individuals |
Eerik Kaseniit |
Poster: 940Apr 5, 10:30 a.m.-12:00 p.m. |
|
Making the Case for Splice Indel Pathogenicity: A Comparison of
Single Nucleotide and Insertion Variants at the +3 Site |
Lea Gemmel |
Poster: 678Apr 5, 10:30 a.m.-11:30 a.m. |
|
Minimizing Results Delivery Time for Couples Undergoing Carrier
Screening by Using a Tandem-Submission-with-Partner-Reflex (“Tandem
Reflex”) Strategy |
Eerik Kaseniit |
Poster: 913Apr 4, 10:30 a.m.-11:30 a.m. |
|
Application of a Severity Framework to 176 Conditions on an
Expanded Carrier Screening Panel |
Aishwarya Arjunan |
Poster: 926Apr 5, 10:30 a.m.-12:00 p.m. |
|
Meeting the Demand for Carrier Screening Results Disclosure and
Patient Management |
Aishwarya Arjunan |
Poster: 616Apr 5, 10:30 a.m.-12:00 p.m. |
|
|
Clarity from Discordance: Leveraging Fetal Fraction Reduces False
Positives in Noninvasive Prenatal Screening. |
Rotem Ben-Shachar |
Poster: 927Apr 4, 10:00 a.m.-11:30 a.m. |
|
Avoiding Unnecessary Trade-Offs: Clinical Experience for a
Noninvasive Prenatal Screen with Both Low No-Call Rate and High
Accuracy |
Susan Hancock |
Poster: 911Apr 4, 10:00 a.m.-11:30 a.m. |
Prequel™ Prenatal Screen |
Leveraging Whole Genome Sequencing in Noninvasive Prenatal
Screening: A Case of Prader Willi Syndrome Due to Uniparental
Disomy. |
Susan Hancock |
Poster: 922Apr 5, 10:30 a.m.-12:00 p.m. |
|
Clinical Experience for a Noninvasive Prenatal Screen in Assisted
Reproductive Technology Pregnancies |
Susan Hancock |
Poster: 946Apr 5, 10:30 a.m.-12:00 p.m. |
|
Rare Adds Up: Characterization of Mosaicism in Expanded Aneuploidy
Analysis via Noninvasive Prenatal Screening |
Albert Lee |
Poster: 936Apr 5, 10:30 a.m.-12:00 p.m. |
|
About Myriad myRisk® Hereditary
CancerThe Myriad myRisk Hereditary Cancer test uses an
extensive number of sophisticated technologies and proprietary
algorithms to evaluate 35 clinically significant genes associated
with eight hereditary cancer sites including: breast, colon,
ovarian, endometrial, pancreatic, prostate and gastric cancers and
melanoma.
About Foresight® Carrier
ScreenThe Myriad Foresight Carrier Screen is designed to
maximize detection of at-risk couples for serious, prevalent, and
clinically-actionable conditions. Foresight has a rigorous disease
selection that focuses on 175+ conditions that provides meaningful
information to patients. Additionally, Foresight offers superior
technology with unmatched detection rates for the vast majority of
genes on the panel (>99% across ethnicities) which means
patients can trust both positive and negative results.
About PrequelTM Prenatal
ScreenThe Myriad Prequel Prenatal Screen is a noninvasive
prenatal screen that uses cell-free DNA (cfDNA) to determine if a
pregnancy is at an increased risk for chromosome abnormalities,
such as Down syndrome. Prequel has been shown to be superior
to screening methods that use maternal age, ultrasound and serum
screening. Additionally, Prequel has a lower false-positive
rate and false-negative rate than these other methods. The
Prequel Prenatal Screen can be ordered with the Foresight Carrier
Screen and offered to all women, including those with high body
mass index, and ovum donor or a twin pregnancy.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five strategic imperatives: build upon a solid hereditary
cancer foundation, growing new product volume, expanding
reimbursement coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer,
myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris,
Foresight and Prequel are trademarks or registered trademarks of
Myriad Genetics, Inc. or its wholly owned subsidiaries in the
United States and foreign countries. MYGN-F, MYGN-G.
Safe Harbor StatementThis press release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements related to the Company’s presentation of new data for
its expanded carrier and noninvasive prenatal screens being
featured at the 2019 Annual Clinical Genetics Meeting April 2-6,
2019 in Seattle; and the Company's strategic directives under the
caption "About Myriad Genetics." These "forward-looking
statements" are based on management's current expectations of
future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by forward-looking
statements. These risks and uncertainties include, but are not
limited to: the risk that sales and profit margins of our molecular
diagnostic tests and pharmaceutical and clinical services may
decline; risks related to our ability to transition from our
existing product portfolio to our new tests, including unexpected
costs and delays; risks related to decisions or changes in
governmental or private insurers’ reimbursement levels for our
tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services and any future tests and services are terminated
or cannot be maintained on satisfactory terms; risks related to
delays or other problems with operating our laboratory testing
facilities and our healthcare clinic; risks related to public
concern over genetic testing in general or our tests in particular;
risks related to regulatory requirements or enforcement in the
United States and foreign countries and changes in the structure of
the healthcare system or healthcare payment systems; risks related
to our ability to obtain new corporate collaborations or licenses
and acquire new technologies or businesses on satisfactory terms,
if at all; risks related to our ability to successfully integrate
and derive benefits from any technologies or businesses that we
license or acquire; risks related to our projections about our
business, results of operations and financial condition; risks
related to the potential market opportunity for our products and
services; the risk that we or our licensors may be unable to
protect or that third parties will infringe the proprietary
technologies underlying our tests; the risk of patent-infringement
claims or challenges to the validity of our patents or other
intellectual property; risks related to changes in intellectual
property laws covering our molecular diagnostic tests and
pharmaceutical and clinical services and patents or enforcement in
the United States and foreign countries, such as the Supreme Court
decision in the lawsuit brought against us by the Association for
Molecular Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; the risk that we may be unable to comply with
financial operating covenants under our credit or lending
agreements; the risk that we will be unable to pay, when due,
amounts due under our credit or lending agreements; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our most recent Annual Report on Form 10-K for the
fiscal year ended June 30, 2018, which has been filed with the
Securities and Exchange Commission, as well as any updates to those
risk factors filed from time to time in our Quarterly Reports on
Form 10-Q or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and Myriad
undertakes no duty to update this information unless required by
law.
Media Contact: Ron Rogers
(801) 584-3065rrogers@myriad.com
Investor Contact: Scott Gleason(801)
584-1143sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024